Gadoxetate Disodium
CAS: 135326-22-6
Ref. 3D-KFA32622
1mg | Discontinued | ||
2mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued |
Product Information
- Gadoxetate Disodium [USAN]
- gadolinium ethoxybenzyl DTPA
- Bay 86-4873
- Disodium (N-((2S)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-)
- Eovist
- Eovist injection
- Gadolinium EOB DTPA
- Gadoxetic acid disodium
- Gd-(S)-EOB-DTPA
- Primovist
- See more synonyms
- Primovist/Eovist
- Unii-Hoy74Vze0M
- Zk 139834
- Gadolinate(2-), (N-(2-(bis((carboxy-kappaO)methyl)amino-kappaN)-3-(4-ethoxyphenyl)propyl)-N-(2-(bis((carboxy-kappaO)methyl)amino-kappaN)ethyl)glycinato(5-)-kappaN,kappaO)-, disodium, (SA-8-11252634-(S))-
Gadoxetate disodium is a gadolinium-based contrast agent used for the diagnosis of liver lesions, as well as for imaging of other organs and tissues. Gadoxetate disodium is administered intravenously and binds to hepatobiliary tissues by the process of passive diffusion. It is excreted unchanged in the urine and has no detectable toxicity in humans. Gadoxetate disodium has been shown to be safe for use in children, with no evidence of adverse effects on growth or development.
Gadoxetate Disodium is a gadolinium-based contrast agent used for the diagnosis of liver lesions, as well as for imaging of other organs and tissues.
Gadoxetate Disodium is administered intravenously and binds to hepatobiliary tissues by the process of passive diffusion.
It is excreted unchanged in the urine and has no detectable toxicity in humans.
Gadoxetate Disodium has been shown to be